
Selinexor plus ruxolitinib combo cuts spleen size by 50% in myelofibrosis patients, showing survival benefits.
The Phase 3 SENTRY trial showed that combining selinexor (NEXPOVIO®) with ruxolitinib significantly improved spleen volume reduction by 49.8% at week 24 compared to 28% with ruxolitinib alone in myelofibrosis patients. This combination also showed a ...

